CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Jiangsu Hengrui Pharmaceuticals

Alexander Bernikov, Medical Director, Clinical Development (Uro)-Oncology

Leveraging AI/ML to Transform Pharmaceutical Industry

Alexander Bernikov

Alexander Bernikov

Based on numerous publications and analysis, high readiness to innovation with utilising modern technologies extensively helps companies to develop services and products in a more efficient way and within shorten timelines.


Despite several pharmaceutical giants are listed among the readiest innovators, overall use of innovative approaches by pharmaceutical industry remains on a relatively low level. And this needs to and will be improved in the nearest future. What do we know about the options to consider? There are dozens of them, and one of the most interesting is artificial intelligence (AI) and machine learning (ML). AI and ML are more and more actively coming to the market, providing novel services and solutions for different industries in fulfilling different routine needs and bringing results with fewer resources spent.


AI/ML has a great potential to transform pharmaceutical industry, for example, with drug discovery, with accelerating timelines of research and development, etc. Thus, helping new drugs to get quicker approval and by this getting to the market faster with a higher chance to become more affordable for payers.


Let’s briefly highlight several applications of AI/ML in pharmaceutical industry:


1. Drug Discovery Process and Design


Design of new molecules, identifying of the drug targets with its validation plays one of the key roles in the success of the whole development program. And AI/ML can step here in, by so leading to the reduction of time required for the entire development process.


2. Research and Development


 Having targets identified, and novel molecules designed, AI/ML can exceptionally help with identification of diseases patterns, suitable formulations, or specific symptoms of diseases that can benefit most and lead to successful outcomes from novel assets in development.


 3. Diagnosis


With evolving of IT security, patients’ electronic medical records (EMR) are more often stored in a centralized storage or in a cloud. Analyzing this data with the help of AI/ML physicians have option to assess effects of different traits and treatments like lifestyle, genetic results, medicines, etc., on a patient’s health and to help physician with a proper treatment selection for the patient.


4. Epidemic Prediction


AI/ML can help to monitor and assess how infections are spreading worldwide by gathering and analyzing information collected from open sources like web. There are already predicting models available. Malaria outbreak prediction model be one of examples that helps healthcare providers to take the best actions in fighting against this disease.


There are no doubts that soon we will see a boom in the implementation of AI/ML in the pharmaceutical industry


5. Identifying Clinical Trials Candidates


Healthcare providers, including physicians participating in the studies, can identify eligible patients, i.e., using specific inclusion/exclusion criteria while searching through the EMR databases. Utilizing AI/ML can help to work with EMR databases and collect, process and analyze giant volumes of patients’ data. As this technology can process and analyze massive amount of data quickly, this leads to the faster identification of patients eligible to participate in the study, quicker enrollment and faster completion of the study.


6. Drug Adherence and Dosage


Patients’ compliance with the study protocol remains an actual problem for the pharmaceutical industry. To avoid distortion in the results, patients not following the rules of the study should be excluded. AI/ML can help with remote monitoring and algorithms that can predict test results by this helping in identifying non-followers among patients.


Above mentioned examples is the tip of the iceberg, among other points of AI/ML application in pharmaceutical industry can be mentioned manufacturing, quality control, marketing, etc.


 As AI/ML can be adjusted to almost any needs and requests, there is growing demand for the sources of data, joint approved rules for safe use of personal and commercial information, relevant transparency and active interactions between stakeholders. There are no doubts that soon we will see a boom in the implementation of AI/ML in the pharmaceutical industry.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/leadership-perspective/leveraging-aiml-to-transform-pharmaceutical-industry-nwid-1046.html